Drugs / Minnelide
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05557851 | Nov 2022 → Jun 2024 | pancreatic adenocarcinoma | Minneamrita Therapeutics LLC | Unknown | No outcome recorded |
| Phase 1 | NCT05166616 | Mar 2022 → Oct 2027 expected | non-small cell lung carcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05566834 | Nov 2020 → Jun 2024 | gastric cancer | Minneamrita Therapeutics LLC | Unknown | No outcome recorded |
| Phase 1 | NCT03760523 | Apr 2019 → Oct 2023 | acute myeloid leukemia | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03347994 | Apr 2018 → Apr 2021 | acute myeloid leukemia | Justin Watts | Withdrawn | No outcome recorded |
| Phase 1 | NCT03129139 | Oct 2017 → Jun 2024 | breast cancer, colorectal cancer, gastric carcinoma, malignant pancreatic neoplasm +1 | Minneamrita Therapeutics LLC | Unknown | No outcome recorded |
| Phase 1 | NCT01927965 | Aug 2013 → Oct 2016 | — | Minneamrita Therapeutics LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04896073 | Mar 2022 → Mar 2025 | pancreatic adenosquamous carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03117920 | Apr 2017 → Jul 2019 | malignant pancreatic neoplasm | Minneamrita Therapeutics LLC | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Minnelide | “Minnelide is a biologically inactive compound that can be broken down in the body to produce a drug that rapidly releases the active compound triptolide when exposed to...” NCT05166616 ↗ |
| Known as | Minnelide 001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01927965 ↗ |
| Known as | MinnelideTM | “This is an open-label, Phase 1b study of MinnelideTM given once a day on Days 1 to 5, Days 8 to12 and Days 15 to 19 in combination with SOC (nab-paclitaxel [Abraxane] plus gemcitabine).” NCT05557851 ↗ |
| Known as | triptolide | “Minnelide™ is a water soluble disodium salt variant of triptolide, a diterpenoid, an HSP70 inhibitor.” NCT05566834 ↗ |
| Action | Inhibit | “heat shock protein (HSP) inhibitor” NCT03129139 ↗ |
| Modality | Small molecule | “Minnelide, a water-soluble disodium salt variant of triptolide, is a diterpenoid heat shock protein 70 (HSP70) inhibitor.” NCT03347994 ↗ |
| Route | Intravenous | “Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period.” NCT01927965 ↗ |
| Target | MYC | “Minnelide is a small molecule anti-superenhancer drug that inhibits MYC.” NCT04896073 ↗ |